Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$2.11 USD
+0.05 (2.43%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $2.12 +0.01 (0.47%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum C VGM
Price, Consensus and EPS Surprise
ESPR 2.11 +0.05(2.43%)
Will ESPR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ESPR
Strength in Kidney Care Likely to Aid DaVita's (DVA) Q2 Earnings
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Product Demand Likely to Aid Organon's (OGN) Q2 Earnings
Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates
Other News for ESPR
Esperion Announces CMO Transition and Continued Advisory Role
Bank of America Securities Sticks to Their Sell Rating for Esperion (ESPR)
Esperion to Report Second Quarter 2024 Financial Results on August 12
Esperion to Participate in Upcoming BTIG Biotech Conference
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the ?Lipid Lurkers? Inside Their Arteries